| Formulations | Generic oral and injectable formulations including specialty and complex drug delivery systems. | Strong ANDA portfolio, regulatory expertise, global distribution, and R&D in biosimilars. | B2B and B2C customers including hospitals, pharmacies, governments, and healthcare providers globally. | Specialty injectables and complex generics deliver highest margins. | 27388 | 86 | Product sales in regulated and emerging pharma markets through wholesales and direct hospital tenders. | Competitive pricing with contracts, tenders, and direct sales; mix of volume and value-based revenues. | New product launches, biosimilars approvals, increased market penetration in USA and Europe. | Bevqolva, Dyrupeg, Zefylti, Auronim |
| Active Pharmaceutical Ingredients (API) | Manufacturing and sale of APIs including semi-synthetic penicillins, cephalosporins and other chemical ingredients. | IP portfolio, GMP certified plants, global regulatory approvals and established customer relationships. | Pharma manufacturers globally (B2B model). | Specialty and high-potency APIs yield higher margins. | 4322 | 14 | Bulk sales to global pharma companies including in-house consumption for formulations. | Contract manufacturing and supply agreements; volume driven. | Backward integration, capacity expansion and regulatory certifications boosting export potential. | |
